Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia
An Open-Label Extension Study to Assess the Long-term Safety and Efficacy of Mipomersen in Subjects With Familial Hypercholesterolemia
Sponsor: Ionis Pharmaceuticals, Inc.
This PHASE2 trial investigates Congenital Abnormalities and Dyslipidemias and is currently completed. Ionis Pharmaceuticals, Inc. leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
May 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ionis Pharmaceuticals, Inc.
- Kastle Therapeutics, LLC
For direct contact, visit the study record on ClinicalTrials.gov .